Skip to content

uniQure QURE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$12.37M
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-59.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$722K-108%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$6.5M+345%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M
ALN
Alnylam PharmaceuticalsALNY
$13.16M-73.3%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's stock issuance proceeds?
uniQure (QURE) reported stock issuance proceeds of $550K in Q1 2026.
How has uniQure's stock issuance proceeds changed year-over-year?
uniQure's stock issuance proceeds increased by 245.9% year-over-year, from $159K to $550K.
What is the long-term trend for uniQure's stock issuance proceeds?
Over 2 years (2022 to 2025), uniQure's stock issuance proceeds has grown at a 177.9% compound annual growth rate (CAGR), from $1.45M to $11.16M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.